- Large treatment-naïve population
- Low costs
- Overall good level of English
The Philippines is the world’s 12th most populous country, with a growing, newly industrialized economy. The capital Manila, home to 12.8 million people, has the highest population density of any city worldwide.
The Philippines is focused on rapidly deploying new and advanced hospital and research facilities and now has over 100 hospitals across the Philippines with substantial clinical trials experience.
This combined with access to a large and mostly treatment naïve population, means the Philippines is an ideal destination for clinical research in key therapeutic areas including cardiovascular, oncology, and infectious, and metabolic diseases.
Importantly also English is the official language and the country has a high number of internationally trained doctors and medical personnel.
While there is disparity in levels of health care available in the community, the Philippines ranks third in in South East Asia in terms of the number of clinical trials conducted, with an annual growth rate of about 30%.
Novotech has established strong clinical teams in the Philippines with deep local knowledge to deliver quality CRO services to biotechnology companies. In addition, it has partnered with key specialist hospital and research facilities including the Asian Eye Institute as part of its Partner Program, giving Novotech clients direct access to the most active and reputable KOLs, PIs and sites to facilitate study start-up and patient recruitment.
Clinical trials are regulated by the Food and Drug Administration Philippines (FDA), Department of Health (DOH), Philippine Council for Health Research and Development (PCHRD) as well as the hospitals’ IEC/IRBs.
Novotech (Australia) Pty Ltd – Philippine Branch
27th floor, Office H, The Podium West, Podium ADB Avenue, Wack Wack, Greenhills East, Mandaluyong City